Ziopharm says committee approves initiation of Phase 1 study of Ad-RTS-IL-12 ZIOPHARM Oncology (ZIOP) announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma. ZIOPHARM has announced plans to launch a Phase 1 study of Ad-RTS-IL-12 in malignant glioma in the first half of 2014. The Company is currently studying Ad-RTS-IL-12 in Phase 2 studies in melanoma and breast cancer. ZIOPHARM is developing Ad-RTS-IL-12 using Intrexon Corporation's (XON) RheoSwitch Therapeutic System platform to control the expression of interleukin-12 and enable its safe and effective delivery as an anti-tumor agent.
News For ZIOP;XON From The Last 14 Days
Check below for free stories on ZIOP;XON the last two weeks.